> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sutro Biopharma Orphan Status for Multiple Myeloma Therapy
- URL: https://www.fdaweb.com/sutro-biopharma-orphan-status-for-multiple-myeloma-therapy/
- Published: 2018-10-12T12:00:00.000Z
- Updated: 2026-09-15T00:37:48.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142578

FDA has granted Sutro Biopharma an orphan drug designation for STRO-001 for treating multiple myeloma. The company says TRO-001 is a potential first-in-class antibody drug conjugate (ADC) targeting CD74, a protein highly expressed in B-cell malignancies. It was developed with Sutro’s cell-free protein synthesis and site-specific conjugation platform, XpressCF+, which “enables design and manufacture of a highly optimized single molecular species within the product, rather than the usual mixture of imprecisely conjugated antibodies that comprise an ADC development product made by conventional cell-based manufacturing platforms,” it says. STRO-001 is currently being studied in a Phase 1 clinical trial enrolling separate dose escalation cohorts for myeloma and B-cell lymphoma.